Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - NUVB News | RalliesNuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program
N
NUVB• Safusidenib glioma program
- Safusidenib was positioned as a brain-penetrant IDH1 inhibitor, with a pivotal SIGMA study enrolling in IDH1-mutant glioma.
Cash position and profitability outlook
- Pro forma cash balance was pegged at about USD 736 million, positioned as sufficient to reach profitability without additional funding.
IBTROZI highlighted as commercial driver
- Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, with U.S. net product revenue of USD 43 million as of March 31, 2026.
- IBTROZI is marketed for advanced ROS1+ NSCLC in the U.S., Japan and China; the EMA validated its marketing authorisation application.
Preclinical Drug-Drug Conjugate platform
- The platform remains preclinical, with candidates designed to bind two targets simultaneously.
Drug-Drug Conjugate
